C4 Therapeutics (CCCC) investor relations material

Vision and strategy

• Aims to become a fully integrated biopharmaceutical company focused on developing best-in-class and first-in-class degraders for oncology and INN (inflammation, neuroinflammation, neurodegeneration) diseases.

• Strategy centers on validated pathways and large market opportunities, with a sustainable pipeline and financial runway through 2028.

• Platform collaborations with major pharma partners expand reach and generate non-dilutive capital.

Clinical pipeline and milestones

• Cemsidomide, an IKZF1/3 degrader, is positioned as a potential foundational therapy for multiple myeloma (MM) across multiple lines of therapy.

• Ongoing Phase 2 MOMENTUM trial and Phase 1b combination trial with elranatamab for MM; additional Phase 1b trials planned.

• Discovery pipeline advancing novel degraders for INN diseases, with three potential INDs targeted by 2028.

Clinical data and efficacy

• Phase 1 cemsidomide + dexamethasone trial enrolled heavily pre-treated MM patients, showing a well-tolerated safety profile with minimal dose reductions and no discontinuations related to cemsidomide.

• Demonstrated deep and durable responses, with ORR up to 53% at higher doses and consistent efficacy across key subgroups.

• Cemsidomide shows potential as a best-in-class IKZF1/3 degrader, with a differentiated safety and efficacy profile compared to first-generation agents.